Skip to search formSkip to main contentSkip to account menu

Altiratinib

An orally bioavailable inhibitor of c-Met/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), Tie2… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

DCC-2701
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The type II switch control kinase inhibitor, DCC-2701 (altiratinib) effectively inhibits resistant NTRK kinase domain mutants
2016
2016
Abstract 4120: c-Met inhibition blocks MEK-induced tumor cell invasion in uveal melanoma
Uveal melanoma is the most common primary intraocular malignant tumor in adults. About half of patients with uveal melanoma will… 
2015
2015
Abstract 4112: Mechanisms of transendothelial migration by invasive breast carcinoma cells from patients
The majority of breast cancer related deaths are not due to the primary tumor, but rather to the dissemination of metastatic… 
2014
2014
356 Discovery of novel pyrido[2,3-b]pyrazine as fibroblast growth factor receptor (FGFR-1, 2, 3 & 4) kinase inhibitors with nanomolar affinity
2014
2014
AI-25THE NOVEL c-MET INHIBITOR ALTIRATINIB (DCC-2701) INHIBITS TUMOR GROWTH AND INVASION IN A BEVACIZUMAB RESISTANT GLIOBLASTOMA MOUSE MODEL
Glioblastoma with acquired resistance to bevacizumab therapy overexpresses c-MET which mediates tumor growth, EMT, invasion, and… 
2014
2014
355 Altiratinib (DCC-2701): a balanced inhibitor of MET, TIE2, and VEGFR2 kinases that exhibits broad anti-tumor and anti-angiogenic activities
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)